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represented by one responder. For recent biomarkers the availability and reimbursement of diagnoses 
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European, countries. Reimbursement of such assessments varies widely between unavailability and payments 
by the health care system or even pharmaceutical companies. The support for testing from alternative 
sources, such as the pharmaceutical industry, is no doubt partly compensating for the lack of public health 
system support, but it is not a viable or long‐term solution. Ideally, a structured access to testing and 
reimbursement should be the aim in order to provide patients with appropriate therapeutic options. As 
biomarker enabled therapies deliver a 50% better probability of outcome success, improved and unbiased 
reimbursement remains a major challenge for the future. 
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Background 
The treatment of lung cancer is a prime example of rapidly 
developing options within current oncology. For optimal 
selection of individual patients for specific treatment, sole 
morphological (cytological or histological) diagnosis is no 
longer sufficient and up-to-date pathological reports should 
in many specific cancer types also include results of testing 
for several multiple molecular markers, namely different 
drugable mutations which can be targeted by modern drugs.
Lung cancer biomarker testing is performed in many 
countries in Europe. The manner in which predictive 
testing is performed, is usually governed and organized 
in a regional or national manner. National guidelines—
sometimes based on international recommendations 
published by organizations like IASLC/CAP/AMP, ESMO, 
NCCN or ASCO—often play an important role (1). 
A report about current situation in molecular testing in 
the central European region has been published recently (2). 
The authors used a questionnaire distributed in 2014-2015. 
This report provided information about non-small cell lung 
cancer management and testing of EGFR and ALK.
To obtain insight in the molecular landscape in more 
countries, a questionnaire of the Ryska paper (2) was 
updated (see Supplementary File) and distributed in 
Western and Central European countries to the pathologists 
participating at the Pulmonary Pathology Society meeting 
26–28 June 2019 in Dubrovnik, Croatia - each country was 
represented by one responder. 
Results and discussion
In total, responses from 21 pathologists from different 
Western and Central European countries were collected 
by the end of May 2019 (response rate 100%). Responses 
were obtained by representative of single institutions of 
a country. It is not excluded that local practices might be 
different than indicated, including variation in ‘on demand’, 
reflex’ or ‘diagnosis and predictive’ testing.
Analysis of the submitted answers indicate that a national 
cancer registry was available in 16 countries and a regional 
registration in an additional one, see Figure 1. The number 
of NSCLC patients per country ranged from 650–55,700 
(mean 13,500).
Diagnostic testing
The sample type used for molecular testing varied 
widely: mean and standard deviation were for ‘Cytology 
only’ 24%±14%, for ‘Histology only’ 45%±23% and for 
‘Histology and Cytology’ 26%±20%. Most responders 
replied that all patients had pathological diagnoses of 
lung cancer, except for 6 responders, where the fraction 
of probable lung cancer patients without a pathological 
diagnosis varied from 2–15%. 
Additional diagnostic (immuno)histochemistry (TTF1, 
p63/p40, mucin staining) is more or less routinely applied: 
mean 62% (range, 10–100%) to further specify the NSCLC 
diagnosis into individual histological subtypes.
The distribution for the histological subtypes was 
(mean and standard deviation): adenocarcinoma 47%±8%, 
squamous cell carcinoma 26%±7%, small cell lung 
carcinoma 15%±3%, NSCLC-not otherwise specified 
6%±3% and others.
Testing guidelines
Awareness of international guidelines of IASLC/CAP/AMP (3), 
ASCO (4), and ESMO (5) was present in all countries. Many 
also have national guidelines: Austria (1) Belgium (6), Czech 
Republic (7), FRANCE (8), Germany (9), Netherlands (10), 
Norway (11), Slovenia (12), Spain (13).
Predictive testing
The inclusion criteria for predictive molecular testing 
were similar in all countries: adenocarcinoma, NSCLC 
favour adenocarcinoma and NSCLC NOS (not otherwise 
specified). In patients with squamous cell carcinoma testing 
was only performed on demand in those with advanced 
disease without a smoking history in line with ESMO (5), 
ASCO (4) and CAP/IASLC/AMP (3) guidelines. PD-L1 is 
tested for all subtypes of NSCLC.
Testing strategy
There are three strategies for predictive testing: ‘on 
demand’, ‘reflex testing’ and ‘diagnosis and prediction’. 
With the ‘on demand’ (also called ‘bespoke’) testing 
approach the request to test is initiated by an oncologist/
pulmonologist treating the patient after receiving the 
pathology report with lung cancer diagnosis. This approach 
has the advantage that only those patients with advanced 
NSCLC are tested, who also fit the clinical inclusion 
criteria for targeted treatment and are therefore in case of 
a positive test result likely to be treated. The disadvantages 
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Figure 1 For 21 involved countries the presence of lung cancer registry is shown: national registry green, regional registry in yellow, no 
registry in blue, white areas did not participate in PPS meeting/“questionnaire”.
Representatives of 21 countries 
responded to the questionair 
(all non-white areas).
National registry for lung cancer
Regional registry
No registry
of this approach are (I) not all patients that may be eligible 
have predictive testing requested, (II) delay in predictive 
test results, as the test request by clinician is based on the 
availability of final histological diagnosis and (III) with 
no tissue management (see below), there is an increasing 
chance of an uninformative test outcome. Thus, in 
cases with small sample size with insufficient amount of 
remaining tumor cells, another biopsy may be necessary 
resulting in an additional delay. Of note, replacing the 
paraffin block in the microtome results in loss of tissue due 
to the uneven positioning in terms of μm, loosing 10–100% 
of the remaining tumor biopsy sample. 
With the ‘reflex testing’ approach, the testing is 
initiated by the pathologist based on a diagnosis fulfilling 
the inclusion criteria. This has the advantages of (I) the 
application of optimal tissue management, and (II) a 
reduction of the waiting time for a predictive test result 
as predictive testing starts before communicating the 
diagnostic report to the clinician. The disadvantage is that 
also patients not eligible for treatment for various reasons 
(such as poor performance status, severe comorbidities, 
rejection of treatment by the patient) or patients with 
lower stages may be tested, some of whom may be cured by 
primary therapy. 
The ‘diagnosis and prediction (D+P)’ approach requires 
a chain organisation based on a request from the clinician 
submitting the tissue (14) to the laboratory handling the 
specimen, through to the reporting process. The process 
starts with the clinician at the time of biopsy with the 
request for predictive testing if the histologic diagnosis fits 
the inclusion criteria. The request for predictive testing 
(D+P code) is printed on the paraffin blocks, indicating to 
the medical scientist/technician a specific cutting protocol 
of approximately 20 additional unstained sections, where 
the first and last will be used for routine haematoxylin and 
eosin stain for diagnostic purpose and the slides in between 
for both diagnostic (immunohistochemistry for tumor 
subtyping) and predictive testing, if the final diagnosis fits 
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the inclusion criteria. This has the advantages that (I) only 
patients with advanced NSCLC will be tested who are likely 
to be treated in case of a positive predictive test are included 
and (II) optimal tissue management. The main disadvantage 
is that the protocol requires very close clinic-pathological 
collaboration and also slightly more handling time. In 
cases which do not fulfil criteria for predictive testing, not 
all initially cut sections are used. Sections ‘in between’ 
the haematoxylin stained sections are used in ~80% of the 
cases for immunohistochemical testing and in ~50% for 
predictive DNA testing.
Based on the responses in the questionnaire, the 
molecular testing strategy of ‘reflex testing’ is applied in 
14 countries, ‘on demand’ testing in 6 countries [Ireland, 
Poland, Portugal, Romania, Serbia, Spain (some on 
demand, some reflex)], and diagnosis and prediction in 1 
(locally in the Netherlands).
Site of testing
Most of the responders indicated that testing is performed 
locally, either in house or in a regional laboratory. The 
exceptions were Portugal with a national central laboratory 
and Romania with testing performed solely in an external 
commercial national or international institute.
Method of testing
Historically, molecular testing in lung cancer was initially 
performed for EGFR mutations with single gene (frequently 
real time PCR) testing. Gradually more genes were 
introduced to the testing process. KRAS mutation analysis 
was occasionally performed with the argument that if positive 
EGFR mutation testing was not necessary, because KRAS and 
EGFR mutations seemed to be mutually exclusive (15). Also, 
in at least one country (Hungary), use of first EGFR TKI 
was initially limited to patients with KRAS wild-type status 
(interestingly, not to EGFR mutant only). In time multiple 
parallel immunohistochemical testing for ALK, PD-L1 and 
recently ROS1 and NRTK IHC was frequently performed 
together with multiple gene testing on DNA.
Subsequently, next generation sequencing (NGS) 
evolved. In practice this meant the testing of mutations 
on a relatively small number of clinically relevant genes in 
one run (targeted NGS). Whole exome or whole genome 
sequencing is currently not performed in routine practice 
for predictive testing. 
Responses to the question “If EGFR testing is performed 
in-house, what testing method(s) was applied were: 17x 
NGS and 5x real time PCR, see Figure 2. The reported 
fraction of inadequate testing ranged from 1–10% (mean 
6%). The turnaround time for EGFR testing varied from 
3–14 (mean 8) workdays.
Availability of predictive testing
EGFR, ALK and PD-L1 testing was available in all 
countries. The antibodies used for PD-L1 were 22C3 
(n=11), SP263 (n=7), SP142 (n=1) and E1L3N (n=1). In 
some countries (e.g., Austria), different laboratories are 
using different clones. Within the centers responding to 
the survey an approved (CE-IVD certified) test was used 
in 11 centres and in 7 a laboratory developed test was 
implemented.
ROS1 testing was available in most countries, except 
for United Kingdom, Romania and Serbia, see Figure 3. 
In Czech Republic, at the time of the responding, ROS1 
was tested on demand. However, since November 2019 
reimbursement was agreed for reflex testing. In Denmark 
ROS1 was fully implemented during the writing period.
Funding for predictive testing
Following the European Medical Agency approval in many 
countries there are tightly regulated procedures for drug 
reimbursement. Frequently the drug can only be given 
when the predictive test is positive. The question is if across 
Europe reimbursement of the predictive test associated 
with the drug is obtained at the same time as the approval 
for the drug. A previous survey by the Central European 
Cooperative Oncology Group showed that both availability 
and reimbursement of testing of molecular alterations in 
NSCLC, which is essential for therapeutic decisions, varies 
widely between these countries (16). Not only is ‘reflex 
testing’ often substituted by analyses performed only ‘on 
demand’, but reimbursement of such assessments varies 
widely between unavailability and payments by the health 
care system or even pharmaceutical companies.
Reimbursement information of the current survey is 
shown in a graphical display for 6 different predictive tests 
(EGFR, ALK, ROS1, PD-L1, Met-Exon 14, and NTRK), 
see Figure 3.
For EGFR testing funding is available in most European 
countries, which evolved around 2010, but in some countries 
(Spain [partly private/public and partly pharmaceutical]], 
Croatia, Servia, Romania) a pharmaceutical company still 
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Figure 2 For 21 involved responders the ‘in house testing method’ is shown at response time June 1 2019: PCR in green; NGS in purple; NGS 
and PCR in blue. During the writing period (November 2019) the following changes were reported: Norway and Portugal NGS and PCR.
Responders ‘in house’
EGFR testing method.
NGS
PCR
NGS and PCR 
fully or partly covers the cost of EGFR testing even in 
2019. For ALK and PD-L1 the situation is more or less 
similar, but for the more recent predictive testing options 
the situation is dramatically worse. 
Country specific funding information
Austria
In Austria,  all  predictive tests for EMA approved 
targeted therapies are reimbursed. There are different 
models of reimbursement, depending on the region, 
and on the provider of the testing (Medical Universities, 
state or private hospitals). This is a complicated system 
since there is no single national health care, or national 
insurance in Austria. Every employee has to be insured by 
the employer. There are several insurance companies and 
there is also insurance for the unemployed and retired 
people covered by the insurance system.
Belgium
In Belgium, a governmental commission has recently 
been set up (ComPerMed) where reimbursement of 
the medication is discussed together with the need 
and reimbursement of a companion diagnostic test. 
Nevertheless, although the time needed for the first part 
has much shortened in recent years, the second part takes 
a lot longer (up to several years), especially in regard to 
immunohistochemical tests performed exclusively by 
pathologists.
Bosnia and Herzegovina
In the Bosnia and Herzegovina there is no separate funding 
for applying predictive testing. Initially after drug approval, 
predictive tests are initially supported by pharmaceutical 
company and is available for all patients. After some time, if 
pharmaceutical company dismiss this support, expenses for 
predictive testing are payed from diagnostic budget.
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EGFR ALK PD-L1
MET exon 14 NTRK BRAF
National health insurance
National health and 
private insurance
Partly private insurance 
Partly pharmaceutical 
company
Pharmaceutical company
Not tested
No information
Not funded, predictive 
testing of diagnostic 
budget
Figure 3 For 21 involved countries way of funding is shown for six predictive tests (EGFR, ALK, PD-L1, MET EXON 14, NTRK and BRAF) 
at response time June 1 2019: national health insurance green, national health insurance and private insurance in blue; partly private insurance 
and partly pharmaceutical company in orange; Pharmaceutical company in purple; tested but finance taken from diagnostic budget in yellow; not 
tested in black; no information in grey. In Slovenia EGFR, ALK and PD-L1 testing is covered by pharmaceutical companies and is supervised by 
national health insurance. During the writing period (November 2019) the following changes were reported: Belgium: NTRK available funded by 
pharmaceutical company; Denmark: ROS1 available; Norway NGS funded includes BRAF and NTRK, the latter on demand; United Kingdom: 
ROS1 tested. Bosnia and Herzegovina: PD-L1 testing funded by pharmaceutical company. Switserland blue and green means “compulsory private 
insurance?”. Added in proof: Croatia EGFR, ALK and PD-L1 testing is covered by national health insurance and pharmaceutical company.
Croatia
National health insurance made recommendations that are 
obligatory for predictive testing in Croatia, what is partly 
payed by National health insurance and partly supported 
by pharmaceutical companies (monoclonal antibodies for 
immunohisto/cytochemistry) and available for all patients.
Czech Republic
The predictive testing on NSCLC in Czech Republic is 
reimbursed by the National Health Insurance. However, 
reimbursement of the test depends on the availability of the 
treatments depending on such test—in other words, only 
tests with direct impact on patients’ clinical management 
are reimbursed. All laboratories register all tested samples 
(specific morphology type, methods used, results of the 
tests) on a voluntary basis in a national pathology registry of 
NSCLC. 
Denmark
In Denmark the validation and application of predictive 
tests in public laboratories are covered from the diagnostic 
budget of the hospitals and there are no formal restrictions 
to availability. The predictive test will normally be 
discussed within the Danish group of lung pathologists 
(DaLuPa) before using it. The predictive tests are generally 
available from the initial period that the drug is available 
for all patients. Private laboratories do not perform these 
predictive tests.
Finland
In Finland the validation and application of predictive 
tests in public laboratories are covered from the diagnostic 
budget of the Health Care District and there are no formal 
restrictions to availability. After the approval of the drug by 
the European Medical Agency, it normally takes six months 
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from the application for the Pharmaceuticals Pricing Board 
of the Ministry of Social Affairs and Health to approve the 
funding and the drug to be available for all patients.
France
In France the process of reimbursement is regulated by 
the French Ministry of Health for the different predictive 
tests in molecular biology. Until recent years, the French 
molecular platforms for oncology testing received a budget 
from the French NCI (Inca) according to their activity and 
the number of tests they did each year. Recently, another 
system of reimbursement has been set up, based on the size 
of the NGS panels used in oncology. This complex mode 
of functioning, called the “Référentiel des actes Innovants 
Hors Nomenclature” (RIHN) has been set up by the 
“Direction Générale de l'Offre de Soins” (DGOS). 
Germany
In Germany, all predictive tests (immunohistochemical 
and molecular analyses) for NSCLC cases which are 
necessary for targeted therapies and are approved by the 
EMA, are reimbursed by health insurance companies. Tests 
and therapy are available for all patients. Approximately 
73 million Germans have a national health insurance plan 
and 9 million Germans have a private health insurance plan. 
There is no significant delay in reimbursement. 
Ireland
In Ireland the Health Service Executive (HSE) fund two 
public centres for molecular testing. Private insurance 
companies also pay for testing for patients with private 
health insurance.
Some hospitals, who wished to develop their own 
molecular testing service, are self-funding from their service 
(diagnostic) budget. In the first year of PDL1 testing in 
Ireland, funding was provided by the HSE but subsequently 
funding was rolled into individual hospital pathology 
departments’ budgets and is performed at five centres. 
Private insurance pays for PDL1 testing for patients with 
private health insurance.
Italy
Although in Italy the health-care system is a regionally 
organized National Health Service (SSN), the Livelli 
Essenziali di Assistenza (LEA) has at national level exclusive 
authority in determining the minimum obligatory tests to 
be performed in all regions. Each region may individually 
define the additional tests (and tariffs). 
Netherlands
In the Netherlands the administrative process of 
reimbursement is tightly regulated in 2 price categories. 
This precludes immediate adaptation of pricing and funding 
of predictive testing when the testing panel increases. 
Nederlandse Zorg Autoriteit (NZA) decides on the testing 
categories. The Dutch Scientific Society proposes the table 
that assigns the various techniques to a category. Hospitals 
subsequently negotiate with the insurance companies and 
payment will be obtained over the next budget year. After 
drug approval (included a separate budget) the delay in 
funding for the test by national health insurance companies 
is around 3 years. Test innovation and validation is not 
covered by health insurance. As the total health care budget 
is restricted, the increasing expenses for predictive testing 
effectively, in most hospitals comes down to a budget cut. 
Nevertheless, predictive tests are generally available from 
the initial period that the drug, but access to testing and the 
completeness of predictive testing varies across hospitals. 
Norway
In Norway all the predictive testing is government funded. 
The outpatient clinic testing is paid for directly by the Helfo 
(The Norwegian Health Economics Administration). For 
NGS there is full reimbursement, but for the immunostains 
(alk, ros1 and PD-L1) and FISH the reimbursement is 
lower than the realistic price. The difference is covered by 
the pathology department's own "diagnostic” budget. The 
inpatient testing is paid for by the budget of the hospital 
department submitting the biopsy/cytology specimen. The 
hospitals that perform predictive testing in Lung Cancer in 
Norway are Public.
Poland
In Poland national health payer (Narodowy Fundusz 
Zdrowia,  NFZ) reimburses  molecular  or  genet ic 
procedures. The cost of routine pathological procedures 
including immunohistochemical tests is incorporated into 
surgical or endoscopic procedures and is also covered by 
NFZ. Immunohistochemical biomarkers (ALK/IHC or 
PD-L1) are not extra paid. The costs of positive PD-L1 
tests are coupled with the treatment for reimbursement 
covered by NFZ. Currently, pharmaceutical company bears 
the costs of negative tests.
Portugal 
In Portugal, National Health Service supports molecular 
pathology tests for every Portuguese citizen. PD-L1 22C3 
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DAKO is supported by industry. Private Hospitals perform 
predictive testing with patient insurance. 
Romania
In Romania predictive tests are usually supported by 
pharmaceuticals company and is available for all patients 
after visiting the oncologist for a ‘pharma voucher’, if the 
patients requires testing before this moment the costs are 
borne by the patient.
Serbia
In the Republic of Serbia the registration of molecular tests 
for oncology diagnostic procedures lays within “Medicines 
and Medical Devices Agency of Serbia (ALIMS)”. After 
the approval by the agency, test can be used for molecular 
diagnostics in oncology. 
All the tests ALIMS approved tests are funded by the 
industry. Thus, not reimbursed by the National Health 
Insurance Fund. Outside this regulation, private testing and 
private application of the drugs is available.
Slovenia
Predictive biomarker testing in lung cancer patients 
follows national recommendations and is available for all 
patients (12). Reimbursement for major predictive tests is 
funded by pharmaceutical companies and is supervised by 
national health insurance company. Other tested predictive 
biomarkers are not reimbursed. 
Spain
In Spain the situation differs between various autonomous 
communities and hospitals. In the past, most testing was 
funded by the pharmaceutical industry but since 2018 
there have been different efforts to finance the testing by 
national health system. Currently, there is a mixture where 
funding is covered by national healthcare authority as part 
of NGS panel in some and in others IHC is provided by 
pharmaceutical industry.
United Kingdom
In the UK, funding for molecular testing comes from the 
National Health Service (NHS) after it has been approved 
by the National Institute for Health and Care Excellence 
(NICE) following an in-depth analysis, including cost-
benefit considerations. Currently, approval by NICE and 
reimbursement is limited to EGFR, ALK, ROS1 and PD-
L1 expression. Additional testing for other molecular tests 
may be performed if relevant for treatments funded by 
the patient via private insurance or other routes such as 
the Cancer Drugs Fund (CDF). New predictive tests are 
typically funded on an ad hoc basis in conjunction with the 
associated pharmaceutical company. 
It should be noted that in England and Wales there 
is a change to move all molecular testing to 7 genomic 
laboratory hubs (GLHs) that will be the sole recipients of 
funding from the NHS for performing any cancer molecular 
tests. This is due to occur in April 2020, and for most 
solid organ tumours molecular profiling will be performed 
with NGS panels, but for specific cases, including some 
haematological and paediatric tumours whole genome 
sequencing (WGS) will also be available and funded.
Switzerland
In Switzerland predictive biomarker testing is available 
for all patients with advanced stage NSCLC and covered 
by health insurance companies. Beside testing for drugs 
approved by the Swiss authority Swissmedic, broad 
molecular profiling is usually performed to allow enrolment 
in clinical trials and access to off label use of available 
drugs. Testing guidelines are provided by the Swiss Society 
of Pathology (17,18) and are closely linked to the NCCN 
guidelines (18). Noteworthy, there are no central regulations 
regarding predictive testing, which allows for dynamic and 
flexible expansion of existing testing algorithms by new 
targets.
Future perspective
That funding is important shows a study of Vrdoljak and 
colleagues, where a correlation of health expenditures 
per capita and mortality-to-incidence ratio is shown (19). 
Large differences in cancer epidemiology, in the majority 
of oncology care parameters and in treatment outcomes, 
exist between Central and Eastern European countries 
and neighbouring Western countries. Mortality-to-
incidence ratios are much less favourable in Central and 
Eastern European countries, and cancer mortality age-
standardized rates are among the worst in the world (2). In 
general, a higher national income and health care budget 
is associated with a higher cancer incidence rate and lower 
mortality rate (12).
In line with a report about lung cancer in Africa and 
the Middle East in countries with a recent history of war 
(or still at war), the development in modern health care, 
expressed in terms of predictive testing for lung cancer, is at 
an essentially slower rate than in other countries or has no 
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recognizable progress (20).
The extension of the questionnaire about molecular 
testing in the central European region (2) shows in this 
study that for recent biomarkers the availability and 
reimbursement of diagnoses of molecular alterations in 
NSCLC, varies widely between different, also western 
European, countries. Reimbursement of such assessments 
varies widely between unavailability and payments by the 
health care system or even pharmaceutical companies. 
The support for testing from alternative sources, 
such as the pharmaceutical industry, is no doubt partly 
compensating for the lack of public health system support, 
but it is not a viable or long-term solution, as it is hampered 
by a series of ethical issues and conflicts of interests (2).
Currently, 74% of the predictive tests are performed 
with a laboratory developed test and 26% with in-vitro 
diagnostics kits (21). An additional future financial hurdle 
is that the European Medical Agency has provided a 
regulation that laboratories should use in-vitro diagnostics 
kits, which are in general much more costly than the 
laboratory developed tests. This will potential have a huge 
financial impact on testing for all countries. This regulation 
is peculiar as after a learning phase laboratory developed 
tests do not perform worse than commercial assays 
(22,23) and, if followed, will especially be beneficial for 
the companies generating these kits at the expense of the 
national health budget. Needless to say, that in countries 
with an already limited health care budget, postponing the 
start of biomarker testing such a regulation backfires and 
has a counterproductive effect.
In the biomarker testing landscape of an increasing 
number of genes needed to be tested, see Figure 3. At 
least for a large number of genes, implementation of 
simultaneous testing of multiple genes at the same time 
using the next-generation sequencing approach in clinical 
diagnostic molecular pathology laboratories is the way 
forward (24). It is likely that for NSCLC the financial 
break-even point between performing in parallel individual 
tests for EGFR, BRAF, Her2, ALK, ROS1, NTRK, MET 
exon14 and PD-L1 and replacement with DNA testing 
for mutations, small deletions/insertions, RNA testing 
for gene fusion and PD-L1 IHC has been reached. This 
change in NGS testing approach definitely requires more 
collaboration between regional laboratories.
Participating in external quality assessment programs 
on predictive testing has been performed in the past in 
some countries France (25), Germany (26), Italy (27,28), 
Netherlands (23) or by nation overarching European 
organisations: ESP (29,30), UKNEQAS (31), EMQN (32), 
NordiQC (22,33) and should be maintained in the future to 
establish predictive testing of optimal quality. The published 
data clearly demonstrate that regular participation in the 
established EQA programs results in improvement of the 
performance of individual laboratories (29,30).
Ideally, a structured access to testing and reimbursement 
should be the aim in order to provide patients with 
appropriate therapeutic options. As biomarker enabled 
therapies deliver a 50% better probability of outcome 
success (21), improved and unbiased reimbursement 
remains a major challenge for the future. 
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NSCLC Molecular testing May 2019
Q1: Does your country have a population-based cancer registry recording data on NSCLC incidence of NSCLC?
Please enter your choice:
□ a. Yes, national registry  If yes, please provide registry name(s):
□ b. Yes, regional registry  If yes, please provide registry name(s): 
□ c. No 
□ d. Don’t know
Q2: What proportion of NSCLC patients in your country have Stage IIIB/IV disease at diagnosis? 
..% in year ….
Answer based on 
□ Data records ; source…..
□ Best estimate 
Q3: In the last year for which data are available, how many cases of NSCLC (any stage) were diagnosed in your country? 
Answer based on 
□ Data records ; source…..
□ Best estimate 
Q4: In 2018, how many cases of NSCLC (any stage) were seen at your centre? 
….. number
Q5: Of these cases in Q4, what proportion was diagnosed using tissue material originating from the following sources (answer 
should total 100%):
Cytology only   …%
Histology only   …%
Concurrent histology and cytology …%
No microscopic diagnosis  …%
Q6: For each stage of disease shown below, please indicate the proportion of NSCLC patients at your centre for whom a 
surgical sample from the primary tumour is available?
Stage I …%
Stage II  …%
Stage III …%
Stage IV …%
Q7: How many hospitals in your country, where lung cancer is treated, have an in-house pathology department that 
routinely performs morphological diagnostics (cytology and/or histopathology) of lung cancer? 
Number: ….
Q8:	 In	what	proportion	of	NSCLC	cases	tested	by	your	laboratory	in	2018	was	immunohistochemistry	used	to	confirm/
finalise	the	histological	diagnosis	(TTF1,	p63/p40,	mucin	stain,	..etc.)?
Percentage: …%
Q9:	 What	proportion	of	the	lung	cancer	cases	diagnosed	in	your	country	are	classified	as	the	following	histological	subtypes?
Adenocarcinoma (incl favour adeno) …%
Squamous cell carcinoma (incl favour SqCC) …%
Supplementary
NSCLC	NOS	(biopsy	only	by	definition)	 …%
Small cell carcinoma …%
Large	cell	carcinoma	(resection	specimen	only	by	definition)	 …%
Other  …%
Q10: Are NSCLC patients in your country currently tested for mutation status?
□ a. Yes, all of them 
□ b. Yes, some of them 
□ c. No 
□ d. Don’t know
Q11: How is EGFR testing in your country currently funded? (Please specify all that apply)
Please specify all that apply:
□ a. National healthcare authority 
□ b. National health insurance company 
□ c. Private insurance 
□ d. Pharmaceutical industry 
□ e. Other source(s); please provide details
□ f. No funding
Q12: Which histological subtypes of NSCLC are tested for mutation status in your country? (Please specify all that apply)
□ Adenocarcinoma (incl favour adeno)
□ Squamous cell carcinoma (incl favour SqCC)
□ NSCLC	NOS	(biopsy	only	by	definition)
□ Small cell carcinoma
□ Large	cell	carcinoma	(resection	specimen	only	by	definition)
□ Other 
Q13: Does your country follow guidelines to select which histological subtypes of NSCLC undergo EGFR testing?
□ a. Yes, national testing guidelines 
□ b. Yes, European testing guidelines 
□ c. Yes, local guidelines 
□ d. Yes, other guidelines 
□ e. No, we have no guidelines 
□ f.	No,	we	cannot	follow	them	(due	to	financial	limitations,	tissue	availability,	lack	of	cooperation,	etc.)	
If you follow guidelines to guide EGFR testing, please provide a reference*) 
……….
*) PMID/website link/attach PDF please, if locoregional
Q14: Does your centre follow guidelines to select which histological subtypes of NSCLC undergo EGFR testing?
□ a. Yes, national testing guidelines 
□ b. Yes, European testing guidelines 
□ c. Yes, local guidelines 
□ d. Yes, other guidelines 
□ e. No, we have no guidelines 
□ f.	No,	we	cannot	follow	them	(due	to	financial	limitations,	tissue	availability,	lack	of	cooperation,	etc.)	
If you follow guidelines to guide EGFR testing, please provide a reference*)
…..
*) PMID/website link/attach PDF please, if locoregional
Q15: Which stages of NSCLC are tested for mutation status at initial diagnosis at your centre?
□ a. All stages 
□ b. Stage IIIB and stage IV only 
□ c. Do not know 
Q16: Which strategy is used for EGFR testing?
□ a.	Reflex	testing:	every	patient	is	tested	automatically	(based	on	histological	type)	
□ b. On-demand: requested by the clinician who took the biopsy 
□ c. On-demand: requested by clinician who is treating the patient (e.g., oncologist) 
□ d. Other strategy (please specify): ………..
Q17: In what proportion of the NSCLC cases which are eligible for EGFR testing in your country is testing actually 
performed?
Percentage:  …. %
Q18: In what proportion of the NSCLC cases eligible for testing at your centre is EGFR testing actually performed?
Percentage:  …. %
Q19:	Please	list	any	exclusion	criteria	inclusion/exclusion	criteria	for	EGFR	testing	in	your	country?	E.g.,	gender,	smoking	
history, performance status, KRAS status, etc.
…………………………………… ………………………………. …………………………… …………………..
Q20: Where is EGFR testing for the NSCLC patients treated at your centre performed? 
□ a. In-house testing laboratory 
□ b.	External	national	laboratory	
□ c.	External	laboratory	(outside	of	your	country)	
□ d.	External	national	commercial	laboratory	
□ e.	External	international	commercial	laboratory	(outside	of	your	country)
Q21: If EGFR testing is performed in-house, what test method(s) do you use?
Please specify all that apply:
□ a. Direct sequencing 
□ b.	Immunohistochemistry	with	mutation-specific	antibody	
□ c.	Real-time	PCR	(e.g.,	ARMS,	TheraScreen®,	Cobas®)	
□ d. Pyrosequencing 
□ e. NGS
□ f. WES
□ g. WGS
□ h. Other method please specify: 
□ i. I do not know what method is used
Q22: If EGFR testing is performed in-house, what proportion of tissue specimens are inadequate for testing?
Percentage:  …. %
Q23: Please indicate the reason(s) why specimens are inadequate (answer should total 100%)
a.	Tissue	specimen	too	small:			 	 	 …	%	
b.	Inadequate	fixation/storage	of	tissue	specimen:	 …	%	
c. Not enough tumour cells in the tissue sample:  … % 
d. Other reason(s):      … %
Q24: What is the average turnaround time of EGFR testing for your patients? (I.e. time from when specimen is sent to the 
laboratory	for	analysis	until	final	test	results	are	received.)	
Indicate average number of days: ……
Q25: Is ALK testing available for NSCLC patients in your country?
□ a. Yes; 
□ b. No; 
□ c. Do not know
Q26: Are NSCLC patients in your country currently tested for rearrangements?
□ a. Yes, all of them 
□ b. Yes, some of them selected by histology (indicate histological subtypes that are tested): 
i. Adenocarcinoma (incl. NSCLC, favour adenocarcinoma) 
ii. NSCLC-NOS 
iii. Squamous cell carcinoma (incl. NSCLC favour squamous cell carcinoma) 
iv. Large cell neuroendocrine carcinoma 
v. Other 
□ c. No 
□ d. Don’t know
Q27: How is ALK testing currently funded in your country? 
Please specify all that apply:
□ a. National healthcare authority 
□ b. National health insurance company 
□ c. Private insurance 
□ d. Pharmaceutical industry 
□ e. Other source(s); please provide details
□ f. No funding
Q28:	Please	 list	any	other	 inclusion/exclusion	criteria	 for	ALK	testing	E.g.,	gender,	smoking	history,	performance	status,	
EGFR/KRAS status, etc.
…………………………………… ………………………………. …………………………… ………
Q29: Does your centre follow guidelines to select which histological types of NSCLC undergo ALK testing?
□ a. Yes, national testing guidelines 
□ b. Yes, European testing guidelines 
□ c. Yes, local guidelines 
□ d. Yes, other guidelines 
□ e. No, we have no guidelines 
□ f.	No,	we	cannot	follow	them	(due	to	financial	limitations,	tissue	availability,	lack	of	cooperation,	etc.)	
If you follow guidelines to guide EGFR testing, please provide a reference ………./PMID/attach PDF
Q30: What strategy is used for ALK testing?
□ a.	Reflex	testing:	every	patient	is	tested	automatically	(based	on	histological	type)	
□ b. On-demand: requested by the clinician who took the biopsy 
□ c. On-demand: requested by clinician who is treating the patient (e.g., oncologist) 
□ d. Other strategy (please specify): ………..
Q31: Which stages of NSCLC are tested for rearrangements at the time of the initial diagnosis at your centre?
□ a. All stages 
□ b. Stage IIIB and stage IV only 
□ c. Do not know 
Q32: What method(s) are currently used for ALK testing in your country? (Please specify all that apply, and indicate details of 
specific	antibodies	or	kits	used)
□ a. Immunohistochemistry ; please specify antibody…..
□ b. Immunohistochemical screening, followed by FISH 
□ c. FISH 
□ d.	RT-PCR	
□ e. DNA sequencing 
□ f. Other method, please specify 
Q33: Are lung cancer patients in your country tested for KRAS in NSCLC?
□ a. Yes 
□ b. No
Q34: In your country, are multidisciplinary lung cancer teams established in routine clinical practice?
□ a. Yes 
□ b. No 
□ c. Yes, but only in specialised lung cancer treatment centres 
□ d. Do not know
Q35: In your country, is it mandatory for all lung cancer cases to be discussed by a multidisciplinary tumour board before any 
primary treatment is initiated?
□ a. Yes, according to local guidelines 
□ b. Yes, according to local practice 
□ c. No 
□ d. Selected cases only 
□ e. Do not know
Q36: In reality, what proportion of lung cases are actually discussed at the multidisciplinary tumour board in your country?
Best estimate Percentage: ….....%
Q37: In reality, what proportion of lung cancer cases are actually discussed at the multidisciplinary tumour board at your 
centre?
Best estimate Percentage: ….....%
Q38: Is PD-L1 tested for NSCLC in your centre?
□ a. Yes 
□ b. No 
Q39: Which PD-L1 antibody is used for NSCLC in your centre?
□ a. 22.8 
□ b. 22C3 
□ c. SP263
□ d. SP142 
□ e. Other, please specify: ……….. …….
Q40: How is PD-L1 testing currently funded in your country? 
Please specify all that apply:
□ a. National healthcare authority 
□ b. National health insurance company 
□ c. Private insurance 
□ d. Pharmaceutical industry 
□ e. Other source(s); please provide details
□ f. No funding
Q41:	Is	this	an	approved	assay	or	a	laboratory	developed	test	(LDT)?
□ a. EMA or FDA Approved
□ b.	LDT	
□ c. do not know
Q42: Is this PD-L1 assay clinically validated or technically validated ?
□ a. technically validated
□ b. clinically
□ c. do not know
Q43:	Is	MET	exon	14	skipping	tested	for	NSCLC	in	country?
□ a. Yes  please provide method: … …. ….
□ b. No 
Q44:	If	Yes	on	Q43:	How	is	MET	exon	14	skipping	testing	currently	funded	in	your	country?	
Please specify all that apply:
□ a. National healthcare authority 
□ b. National health insurance company 
□ c. Private insurance 
□ d. Pharmaceutical industry 
□ e. Other source(s); please provide details
□ f. No funding
Q45: Is BRAF mutation tested for NSCLC in your country?
□ a. Yes  please provide method: … …. ….
□ b. No 
Q46: If Yes on Q45: How is BRAF testing currently funded in your country? 
Please specify all that apply:
□ a. National healthcare authority 
□ b. National health insurance company 
□ c. Private insurance 
□ d. Pharmaceutical industry 
□ e. Other source(s); please provide details
□ f. No funding
Q47:	Is	NTRK	fusion	tested	for	NSCLC	in	your	country?
□ a. Yes  please provide method: ..............................
□ b. No 
Q48:	If	Yes	on	Q47:	How	is	NTRK	testing	currently	funded	in	your	country?	
Please specify all that apply:
□ a. National healthcare authority 
□ b. National health insurance company 
□ c. Private insurance 
□ d. Pharmaceutical industry 
□ e. Other source(s); please provide details
□ f. No funding
Q49: Are lung cancer patients in your country tested for any other molecular biomarkers (e.g., NRG1)? Please provide details 
below.
- NRG1
- ROS1?
-	RET?
………… ………….. ………….. ………………..
